Suppr超能文献

肝移植:东方与西方

Liver Transplantation: East versus West.

作者信息

Shukla Akash, Vadeyar Hemant, Rela Mohamed, Shah Samir

机构信息

Institute of Liver Diseases, HPB Surgery and Transplantation, Global Hospital - Superspeciality and Multiorgan Transplant Centre, 35, Dr. E. Borges Road, Hospital Avenue, Mumbai 400012, Maharashtra, India.

出版信息

J Clin Exp Hepatol. 2013 Sep;3(3):243-53. doi: 10.1016/j.jceh.2013.08.004. Epub 2013 Sep 12.

Abstract

Liver transplantation (LT) has evolved rapidly since the first successful liver transplant performed in1967. Despite a humble beginning, this procedure gained widespread acceptance in the western world as a suitable option for patients with end stage liver disease (ESLD) by the beginning of the 1980s. At present, approximately 25,000 liver transplants are being performed worldwide every year with approximately 90% one year survival. The techniques of living donor liver transplantation (LDLT) developed in East Asia in the 1990s to overcome the shortage of suitable grafts for children and scarcity of deceased donors. While deceased donor liver transplantation (DDLT) constitutes more than 90% of LT in the western world, in India and other Asian countries, most transplants are LDLT. Despite the initial disparity, outcomes following LDLT in eastern countries have been quite satisfactory when compared to the western programs. The etiologies of liver failure requiring LT vary in different parts of the world. The commonest etiology for acute liver failure (ALF) leading to LT is drugs in the west and acute viral hepatitis in Asia. The most common indication for LT due to ESLD in west is alcoholic cirrhosis and hepatitis C virus (HCV), while hepatitis B virus (HBV) predominates in the east. There is a variation in prognostic models for assessing candidature and prioritizing organ allocation across the world. Model for end-stage liver disease (MELD) is followed in United States and some European centers. Other European countries rely on the Child-Turcotte-Pugh (CTP) score. Some parts of Asia still follow chronological order of listing. The debate regarding the best model for organ allocation is far from over.

摘要

自1967年首次成功进行肝移植以来,肝移植(LT)发展迅速。尽管起步简陋,但到20世纪80年代初,该手术在西方世界已被广泛接受,成为终末期肝病(ESLD)患者的合适选择。目前,全球每年约进行25000例肝移植,一年生存率约为90%。20世纪90年代,东亚地区开发了活体肝移植(LDLT)技术,以克服儿童合适供肝短缺和脑死亡供体稀缺的问题。在西方世界,脑死亡供体肝移植(DDLT)占肝移植的90%以上,而在印度和其他亚洲国家,大多数移植是LDLT。尽管最初存在差异,但与西方项目相比,东方国家LDLT后的结果相当令人满意。世界各地需要肝移植的肝衰竭病因各不相同。导致肝移植的急性肝衰竭(ALF)最常见的病因在西方是药物,在亚洲是急性病毒性肝炎。西方因ESLD进行肝移植最常见的指征是酒精性肝硬化和丙型肝炎病毒(HCV),而在东方乙型肝炎病毒(HBV)占主导。世界各地在评估候选资格和确定器官分配优先级的预后模型方面存在差异。美国和一些欧洲中心采用终末期肝病模型(MELD)。其他欧洲国家依赖Child-Turcotte-Pugh(CTP)评分。亚洲一些地区仍按登记时间顺序进行。关于最佳器官分配模型的争论远未结束。

相似文献

1
Liver Transplantation: East versus West.肝移植:东方与西方
J Clin Exp Hepatol. 2013 Sep;3(3):243-53. doi: 10.1016/j.jceh.2013.08.004. Epub 2013 Sep 12.
2
Liver Transplantation in India: At the Crossroads.印度的肝脏移植:处于十字路口
J Clin Exp Hepatol. 2015 Dec;5(4):329-40. doi: 10.1016/j.jceh.2015.11.001. Epub 2015 Nov 12.
3
Liver Transplantation Update: 2014.《肝脏移植最新进展:2014年》
Euroasian J Hepatogastroenterol. 2015 Jul-Dec;5(2):98-106. doi: 10.5005/jp-journals-10018-1144. Epub 2016 Jul 9.
4
Liver Transplant in Acute Liver Failure - Looking Back Over 10 Years.急性肝衰竭中的肝移植——回顾十年
J Clin Exp Hepatol. 2020 Jul-Aug;10(4):322-328. doi: 10.1016/j.jceh.2019.10.005. Epub 2019 Oct 31.
5
Living donor liver transplantation for hepatocellular carcinoma.肝细胞癌的活体供肝肝移植
Recent Results Cancer Res. 2013;190:165-79. doi: 10.1007/978-3-642-16037-0_11.
7
Evaluation of liver transplant recipients.肝移植受者的评估
J Clin Exp Hepatol. 2011 Dec;1(3):199-203. doi: 10.1016/S0973-6883(11)60238-7. Epub 2012 Jan 2.

引用本文的文献

1
Factors Associated With Willingness to Become a Living Organ Donor.与愿意成为活体器官捐赠者相关的因素。
JAMA Netw Open. 2025 Aug 1;8(8):e2527592. doi: 10.1001/jamanetworkopen.2025.27592.
5
Trends of liver transplantation in Asia.亚洲肝脏移植的趋势。
Updates Surg. 2024 Jul 24. doi: 10.1007/s13304-024-01924-1.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验